日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma

皮下注射莫苏妥珠单抗联合来那度胺及单药治疗日本复发/难治性滤泡性淋巴瘤患者的疗效和安全性

Makita, Shinichi; Izutsu, Koji; Mishima, Yuko; Kumode, Takahiro; Kuroda, Junya; Kanemura, Nobuhiro; Fukuhara, Noriko; Shimada, Kazuyuki; Mori, Chiemi; Kawasaki, Atsuko; Miyake, Takeshi; Maruyama, Dai

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

维奈托克联合奥妥珠单抗固定疗程治疗未经治疗的日本慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的疗效和安全性:一项 II 期研究

Izutsu, Koji; Watanabe, Mitsumasa; Toubai, Tomomi; Tsukamoto, Taku; Maruyama, Dai; Kumode, Takahiro; Fukuhara, Noriko; Ogawa, Natsumi; Satomi, Natsuko; Nishimura, Yasuko; Honda, Hideyuki; Chyla, Brenda; Takizawa, Jun

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

对 Pola-R-CHP 治疗未经治疗的日本 DLBCL 患者的多中心研究(POLASTAR)的初步分析

Satake, Atsushi; Nagate, Yasuhiro; Miyawaki, Kohta; Fujiwara, Yuki; Ota, Shuichi; Muta, Tsuyoshi; Rai, Shinya; Tsurumi, Hisashi; Suzuki, Ritsuro; Miyake, Takaaki; Goto, Hideki; Fukuhara, Noriko; Sakata-Yanagimoto, Mamiko; Izutsu, Koji; Nishikori, Momoko; Shibayama, Hirohiko; Kumode, Takahiro; Ennishi, Daisuke; Shimose, Takayuki; Inubashiri, Naoki; Matsumura, Itaru; Akashi, Koichi; Kato, Koji

A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study

一项针对复发或难治性惰性非霍奇金淋巴瘤患者的zandelisib II期研究:ME-401-K02研究

Munakata, Wataru; Kumode, Takahiro; Goto, Hideki; Fukuhara, Noriko; Shimoyama, Tatsu; Takeuchi, Masahiro; Kawakita, Toshiro; Kubo, Kohmei; Sawa, Masashi; Uchida, Toshiki; Mishima, Yuko; Ichii, Michiko; Hanaya, Miyoko; Matsumoto, Asuka; Kuriki, Masaaki; Seike, Toshihiro; Izutsu, Koji; Ishizawa, Kenichi

Risk stratification of residual abscess after surgical treatment for gastroduodenal perforation

胃十二指肠穿孔手术治疗后残余脓肿的风险分层

Ishikawa, Kana; Yao, Siyuan; Kumode, Takashi; Tanino, Keisuke; Matsui, Yugo; Honma, Shusaku; Hosokawa, Shinichi; Murakami, Teppei; Kan, Takatsugu; Nakajima, Sanae

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

抗精神病药物氯丙嗪抑制STAT5信号传导,克服由Gatekeeper突变FLT3-ITD/F691L介导的耐药性,并在FLT3-ITD阳性细胞中与Quizartinib产生协同作用。

Fujii-Hanamoto, Aki; Tanaka, Hirokazu; Fujimoto, Ko; Haeno, Takahiro; Miyake, Yoshiaki; Fujiwara, Ryosuke; Kumode, Takahiro; Serizawa, Kentaro; Morita, Yasuyoshi; Hanamoto, Hitoshi; Rai, Shinya; Matsumura, Itaru

Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1

mosunetuzumab 单药治疗日本复发/难治性滤泡性淋巴瘤患者的疗效和安全性:FLMOON-1

Goto, Hideki; Kumode, Takahiro; Mishima, Yuko; Kataoka, Keisuke; Ogawa, Yoshiaki; Kanemura, Nobuhiro; Shimada, Kazuyuki; Uchida, Toshiki; Kuroe, Yukano; Kawasaki, Atsuko; Sato, Jotaro; Teshima, Takanori

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial

epcoritamab治疗日本复发或难治性弥漫性大B细胞淋巴瘤患者的疗效和安全性:EPCORE NHL-3试验的3年随访结果

Izutsu, Koji; Kumode, Takahiro; Yuda, Junichiro; Nagai, Hirokazu; Mishima, Yuko; Suehiro, Youko; Yamamoto, Kazuhito; Fujisaki, Tomoaki; Ishitsuka, Kenji; Ishizawa, Kenichi; Ikezoe, Takayuki; Nishikori, Momoko; Akahane, Daigo; Fujita, Jiro; Jafarinasabian, Pegah; Soong, David; D'Angelo Månsson, Barbara; Takahashi, Ami; Favaro, Elena; Fukuhara, Noriko

CD34(+) and CD34(-) MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34(+) MM cells

CD34(+)和CD34(-) MM细胞表现出不同的免疫检查点分子表达谱:CD34(+) MM细胞高表达CD112和CD137配体。

Fukui-Morimoto, Ayano; Serizawa, Kentaro; Fujimoto, Ko; Hanamoto, Aki; Iwata, Yoshio; Kakutani, Hiroaki; Kumode, Takahiro; Hirase, Chikara; Morita, Yasuyoshi; Tatsumi, Yoichi; Hanamoto, Hitoshi; Tanaka, Hirokazu; Matsumura, Itaru

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study

在日本,伊布替尼治疗慢性淋巴细胞白血病患者的真实世界疗效和安全性:Orbit 研究

Muta, Tsuyoshi; Masamoto, Yosuke; Yamamoto, Go; Kurahashi, Shingo; Kameoka, Yoshihiro; Ota, Shuichi; Matsuki, Eri; Ozeki, Kazutaka; Toyama, Takanori; Takahashi, Naoki; Kumode, Takahiro; Aotsuka, Nobuyuki; Yoshimura, Takuro; Tamura, Hideto; Omi, Ai; Shibayama, Kazuhiro; Watanabe, Aki; Isobe, Yasushi; Kojima, Kensuke; Takizawa, Jun; Nagai, Hirokazu; Suzumiya, Junji; Aoki, Sadao